Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017264 · ClinicalTrials.gov registry record · Phase 1
Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00017264: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00017264 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00017264, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of atrasentan in treating patients who have progressive or recurrent malignant glioma.
Interventions
- DRUG atrasentan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00017264
The ClinicalTrials.gov registry entry for NCT00017264 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which atrasentan hydrochloride is the first listed.
NCT00017264 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00017264 about?
NCT00017264 is a clinical study titled "Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of atrasentan in treating patients who have progressive or recurrent malignant glioma.
What is the current status of trial NCT00017264?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-06.
What interventions are being tested in trial NCT00017264?
The interventions under investigation include: atrasentan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00017264?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.